Investors & Media


February 7, 2022

NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

January 20, 2022

NGM Bio to Participate in Upcoming Investor Conferences

January 10, 2022

NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs

January 6, 2022

NGM Bio to Present at 40th Annual J.P. Morgan Healthcare Conference

Displaying 11 - 14 of 14

Contact Information

investor relations

media relations